BioNTech price target lowered to $151 from $172 at Truist
Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.
mlive21h
Still ‘no red flags’ for COVID vaccine after years of monitoring their safety
Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...
Endpoints News23h
Min­eralys aims to raise $250M; Co­herus dis­clos­es lay­offs
Mineralys Therapeutics plans $250M share offering after lorundrostat's Phase 3 success; Coherus cuts 30% staff; BioNTech's melanoma trial fails ...
MT Newswires on MSN23h
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
European equities traded in the US as American depositary receipts were lower late Tuesday morning, declining 1.03% to 1,388.44 on the S&P Europe Select ADR Index. From continental Europe, the gainers ...